Stuart Elborn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3507842/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug–device combination. Pulmonary Pharmacology and Therapeutics, 2018, 50, 72-79.	2.6	45
2	Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Journal of Cystic Fibrosis, 2016, 15, 634-640.	0.7	40
3	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. Journal of Cystic Fibrosis, 2020, 19, 370-375.	0.7	24
4	Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view. Journal of Cystic Fibrosis, 2020, 19, 688-695.	0.7	14
5	Airway persistence by the emerging multiâ€azoleâ€resistant <i>Rasamsonia argillacea</i> complex in cystic fibrosis. Mycoses, 2018, 61, 665-673.	4.0	13
6	Antimicrobial resistance: Concerns of healthcare providers and people with CF. Journal of Cystic Fibrosis, 2021, 20, 407-412.	0.7	13
7	Bronchiectasis and inhaled tobramycin: A literature review. Respiratory Medicine, 2022, 192, 106728.	2.9	11
8	Infection with Prevotella nigrescens induces TLR2 signalling and low levels of p65 mediated inflammation in Cystic Fibrosis bronchial epithelial cells. Journal of Cystic Fibrosis, 2020, 19, 211-218.	0.7	8
9	Management of chronic <i>Pseudomonas aeruginosa</i> infection with inhaled levofloxacin in people with cystic fibrosis. Future Microbiology, 2021, 16, 1087-1104.	2.0	7
10	CFTR Modulators: Deciding What Is Best for Individuals in an Era of Precision Medicine. Annals of the American Thoracic Society, 2018, 15, 298-300.	3.2	6
11	Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult βENaC-Tg Mice. Mediators of Inflammation, 2021, 2021, 1-10.	3.0	3